Avaxia Biologics ( www.avaxiabiologics.com ) is a development stage company developing oral antibody therapeutics that act locally within the gastrointestinal tract. The antibodies are designed to treat both diseases of the GI tract and metabolic diseases. Using its proprietary antibody platform, Avaxia is developing products for inflammatory bowel disease, GI acute radiation syndrome, celiac disease, oral mucositis, diabetes and obesity.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/14/12 | $4,100,000 | Series A |
Beacon Angels Cherrystone Angels Mass Medical Angels North Country Angels | undisclosed |
